Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Professor
Graduate School
Graduate School of Medicine
Title
Professor
External link
ANDO Yuichi
Degree 1
-
医学博士 （ 1999.3 名古屋大学 ）
Research Interests 1
-
clinical oncology
Research Areas 1
-
Others / Others / 臨床腫瘍学
Research History 4
-
Nagoya University Professor
2012.5
Country：Japan
-
Nagoya University
2022.4
-
Nagoya University
2022.4
-
Nagoya University Nagoya University Hospital
2018.8 - 2022.3
Education 2
-
Nagoya University Graduate School, Division of Medical Sciences
1996.4 - 1999.3
Country： Japan
-
Nagoya University Faculty of Medicine
1984.4 - 1990.3
Country： Japan
Professional Memberships 7
-
日本臨床腫瘍学会 理事
-
日本癌学会 評議員
-
日本臨床薬理学会 理事
-
日本がん治療学会
-
American Society of Clinical Oncology
-
日本呼吸器学会
-
日本緩和医療学会
Awards 1
-
日本癌学会奨励賞
2004
Papers 98
-
Consent in Pharmacogenetic Testing.
Ando Y, Terada T
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Vol. 41 ( 22 ) page： 3875 2023.8
-
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Ando Yuichi, Nishiyama Hiroyuki, Shimodaira Hideki, Takano Nao, Sakaida Emiko, Matsumoto Koji, Nakanishi Koki, Sakai Hideki, Tsukamoto Shokichi, Komine Keigo, Yasuda Yoshinari, Kato Taigo, Fujiwara Yutaka, Koyama Takafumi, Kitamura Hiroshi, Kuwabara Takashige, Yonezawa Atsushi, Okumura Yuta, Yakushijin Kimikazu, Nozawa Kazuki, Goto Hideaki, Matsubara Takeshi, Hoshino Junichi, Yanagita Motoko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 2023.7
-
A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan
Matsuoka Ayumu, Shimazu Taichi, Takahashi Masahiro, Nagashima Fumio, Nishiyama Hiroyuki, Fujimori Maiko, Ando Yuichi
JOURNAL OF GERIATRIC ONCOLOGY Vol. 14 ( 1 ) page： 101399 2023.1
-
A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
Ando Yuichi, Morita Sachi, Shimokata Tomoya, Tsuzuki Toyonori, Inafuku Shigeru, Iwami Kenichiro, Brega Nicoletta, Akagawa Takashi, Tsujino Toshiaki, Ogawa Tetsuya
INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 4 ) page： 242 - 246 2022.10
-
A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy
Liang Yao, Maeda Osamu, Miyata Kazushi, Tanaka Chie, Kanda Mitsuro, Shimizu Dai, Fukaya Masahide, Koike Masahiko, Kodera Yasuhiro, Ando Yuichi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2023.7
-
Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer
Hatta Takahiro, Hase Tetsunari, Hara Toru, Kimura Tomoki, Kojima Eiji, Abe Takashi, Horio Yoshitsugu, Goto Yasuhiro, Ozawa Naoya, Yogo Naoyuki, Shibata Hirofumi, Shimokata Tomoya, Oguri Tetsuya, Yamamoto Masashi, Yanagisawa Kiyoshi, Ando Masahiko, Ando Yuichi, Kondo Masashi, Ishii Makoto, Hasegawa Yoshinori
CANCER MEDICINE Vol. 12 ( 15 ) page： 15955 - 15969 2023.6
-
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis
Yamamoto Takafumi, Mizuno Kazuyuki, Ito Takanori, Yokoyama Shinya, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Ishikawa Takuya, Kanamori Akira, Yasuda Satoshi, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Nishio Naoki, Maeda Osamu, Ishii Makoto, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Ishigami Masatoshi, Kawashima Hiroki
INVESTIGATIONAL NEW DRUGS Vol. 41 ( 3 ) page： 512 - 521 2023.6
-
Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer
Liang Yao, Maeda Osamu, Miyata Kazushi, Kanda Mitsuro, Shimizu Dai, Sugita Shizuki, Okada Tohru, Ito Junji, Kawamura Mariko, Ishihara Shunichi, Nakatochi Masahiro, Ando Masahiko, Kodera Yasuhiro, Ando Yuichi
MOLECULAR AND CLINICAL ONCOLOGY Vol. 18 ( 4 ) page： 34 2023.4
-
Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury
Yamamoto Takafumi, Morooka Hikaru, Ito Takanori, Ishigami Masatoshi, Mizuno Kazuyuki, Yokoyama Shinya, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Yokota Kenji, Hase Tetsunari, Maeda Osamu, Hashimoto Naozumi, Ando Yuichi, Akiyama Masashi, Kawashima Hiroki
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 38 ( 2 ) page： 251 - 258 2023.2
-
Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study
Maeda Osamu, Fukaya Masahide, Koike Masahiko, Miyata Kazushi, Kanda Mitsuro, Nishida Kazuki, Ando Masahiko, Kodera Yasuhiro, Ando Yuichi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 ( 6 ) page： 578 - 585 2022.12
-
Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment
Maeda Osamu, Matsuoka Ayumu, Yanagawa Madoka, Muroyama Yukie, Watanabe Kazuhisa, Liang Yao, Ishikawa Takuya, Ohno Eizaburo, Kawashima Hiroki, Umegaki Hiroyuki, Kuzuya Masafumi, Ando Yuichi
JOURNAL OF GERIATRIC ONCOLOGY Vol. 13 ( 8 ) page： 1260 - 1263 2022.11
-
A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors
Morita Sachi, Minami Hironobu, Mitsuma Ayako, Toyoda Masanori, Kiyota Naomi, Ando Yuichi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 ( 5 ) page： E427 - E434 2022.10
-
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade
Kobayashi Tomoko, Iwama Shintaro, Yamagami Ayana, Yasuda Yoshinori, Okuji Takayuki, Ito Masaaki, Zhou Xin, Ando Masahiko, Onoue Takeshi, Miyata Takashi, Sugiyama Mariko, Hagiwara Daisuke, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Ito Takanori, Kikumori Toyone, Inoue Megumi, Ando Yuichi, Masuda Norikazu, Kawashima Hiroki, Hashimoto Naozumi, Arima Hiroshi
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Vol. 107 ( 10 ) page： E4115 - E4123 2022.9
-
Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association
Yamaguchi Takahiro, Sugiyama Yutaka, Tanaka Toshiaki, Kimura Tomokazu, Yumura Yasushi, Nakano Masahiro, Sugiyama Takayuki, Miura Noriyoshi, Goya Masato, Yamamoto Akira, Takahashi Satoru, Miura Yuji, Tsuzuki Toyonori, Masumori Naoya, Nishiyama Hiroyuki, Yao Masahiro, Koie Takuya, Miyake Hideaki, Saika Takashi, Saito Seiichi, Akimoto Tetsuo, Tamada Tsutomu, Ando Yuichi, Takahashi Satoru, Suzuki Takaaki, Hinotsu Shiro, Kamba Tomomi
INTERNATIONAL JOURNAL OF UROLOGY Vol. 29 ( 8 ) page： 780 - 792 2022.8
-
Clinical impact of standardized creatinine on dose adjustment of capecitabine
Ito Ayaka, Ichikawa Kazuya, Miyazaki Masayuki, Sagara Atsunobu, Motegi Toshiki, Ando Yuichi, Senzaki Koji, Nagai Taku, Yamada Kiyofumi
NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 84 ( 3 ) page： 547 - 553 2022.8
-
Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.
Mitsuma A, Ito Y, Shimokata T, Tanaka C, Uehara K, Nakayama G, Terasaki H, Ando Y
Cancer diagnosis & prognosis Vol. 2 ( 3 ) page： 330 - 335 2022.5
-
Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
Iwama Shintaro, Kobayashi Tomoko, Yasuda Yoshinori, Okuji Takayuki, Ito Masaaki, Ando Masahiko, Zhou Xin, Yamagami Ayana, Onoue Takeshi, Kawaguchi Yohei, Miyata Takashi, Sugiyama Mariko, Takagi Hiroshi, Hagiwara Daisuke, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Wakahara Keiko, Yokota Kenji, Kato Masashi, Nishio Naoki, Tanaka Chie, Miyata Kazushi, Ogura Atsushi, Ito Takanori, Sawada Tsunaki, Shimokata Tomoya, Niimi Kaoru, Ohka Fumiharu, Ishigami Masatoshi, Gotoh Momokazu, Hashimoto Naozumi, Saito Ryuta, Kiyoi Hitoshi, Kajiyama Hiroaki, Ando Yuichi, Hibi Hideharu, Sone Michihiko, Akiyama Masashi, Kodera Yasuhiro, Arima Hiroshi
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Vol. 107 ( 4 ) page： E1620 - E1630 2022.3
-
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade
Miyai Yuki, Sugiyama Daisuke, Hase Tetsunari, Asai Naoya, Taki Tetsuro, Nishida Kazuki, Fukui Takayuki, Chen-Yoshikawa Toyofumi Fengshi, Kobayashi Hiroki, Mii Shinji, Shiraki Yukihiro, Hasegawa Yoshinori, Nishikawa Hiroyoshi, Ando Yuichi, Takahashi Masahide, Enomoto Atsushi
LIFE SCIENCE ALLIANCE Vol. 5 ( 6 ) 2022.3
-
[Chemotherapy for Older Patients with Cancer].
Mitsuma A, Ando Y
Gan to kagaku ryoho. Cancer & chemotherapy Vol. 49 ( 1 ) page： 13 - 18 2022.1
-
Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)
Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi
INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 1 ) page： 49 - 49 2022.1
-
Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi
INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 1 ) page： 46 - 48 2022.1
-
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi
INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 1 ) page： 67 - 70 2022.1
-
COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective
Nishiwaki Satoshi, Ando Yuichi
FRONTIERS IN MEDICINE Vol. 8 page： 812370 2021.12
-
Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
Kanda Mitsuro, Shimizu Dai, Miyata Kazushi, Maeda Osamu, Tanaka Chie, Inokawa Yoshikuni, Hattori Norofumi, Hayashi Masamichi, Ando Masahiko, Kuwatsuka Yachiyo, Murotani Kenta, Nakayama Goro, Koike Masahiko, Ando Yuichi, Ebata Tomoki, Kodera Yasuhiro
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS Vol. 24 page： 100853 2021.12
-
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
Schoffski Patrick, Concin Nicole, Suarez Cristina, Subbiah Vivek, Ando Yuichi, Ruan Shiling, Wagner Joel P., Mansfield Keith, Zhu Xu, Origuchi Shizuka, DiDominick Sarah, Bialucha Carl U., Faris Jason E., Tran Ben
ONCOLOGY RESEARCH AND TREATMENT Vol. 44 ( 10 ) page： 547 - 556 2021.10
-
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies
Ito Takanori, Ishigami Masatoshi, Yamamoto Takafumi, Mizuno Kazuyuki, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Kawashima Hiroki, Yasuda Satoshi, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Nishio Naoki, Maeda Osamu, Kato Masashi, Hashimoto Naozumi, Hibi Hideharu, Kodera Yasuhiro, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Shimoyama Yoshie, Fujishiro Mitsuhiro
HEPATOLOGY INTERNATIONAL Vol. 15 ( 5 ) page： 1278 - 1287 2021.10
-
Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review
Kazama Shingo, Morimoto Ryota, Kimura Yuki, Shibata Naoki, Ozaki Reina, Araki Takashi, Mizutani Takashi, Oishi Hideo, Arao Yoshihito, Kuwayama Tasuku, Hiraiwa Hiroaki, Kondo Toru, Furusawa Kenji, Shimokata Tomoya, Okumura Takahiro, Bando Yasuko K., Ando Yuichi, Murohara Toyoaki
CARDIO-ONCOLOGY Vol. 7 ( 1 ) page： 26 2021.7
-
A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab
Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 32 page： S354 - S354 2021.7
-
Guidelines for clinical evaluation of anti-cancer drugs
Minami Hironobu, Kiyota Naomi, Kimbara Shiro, Ando Yuichi, Shimokata Tomoya, Ohtsu Atsushi, Fuse Nozomu, Kuboki Yasutoshi, Shimizu Toshio, Yamamoto Noboru, Nishio Kazuto, Kawakami Yutaka, Nihira Shin-ichi, Sase Kazuhiro, Nonaka Takahiro, Takahashi Hideaki, Komori Yukiko, Kiyohara Koshin
CANCER SCIENCE Vol. 112 ( 7 ) page： 2563 - 2577 2021.7
-
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Wick Antje, Baehr Oliver, Schuler Martin, Rohrberg Kristoffer, Chawla Sant P., Janku Filip, Schiff David, Heinemann Volker, Narita Yoshitaka, Lenz Heinz-Josef, Ikeda Masafumi, Ando Yuichi, Wick Wolfgang, Steinbach Joachim P., Burger Michael C., Wenger Katharina, Lassen Ulrik, Sankhala Kamalesh K., Roggia Cristiana, Genvresse Isabelle, Munhoz Catya, Rentzsch Christine, Reschke Susanne, Langer Simon, Wagner Markus, Kaulfuss Stefan, Cai Charles, Lagkadinou Eleni, Jeffers Michael, Pena Carol, Tabatabai Ghazaleh
CLINICAL CANCER RESEARCH Vol. 27 ( 10 ) page： 2723 - 2733 2021.5
-
Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies
Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi
CANCER SCIENCE Vol. 112 ( 2 ) page： 725 - 733 2021.2
-
Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)
Nakayama Goro, Takano Nao, Taniguchi Hiroya, Ishigure Kiyoshi, Yokoyama Hiroyuki, Teramoto Hitoshi, Hashimoto Ryoji, Sakai Mitsuru, Ishiyama Akiharu, Kinoshita Takashi, Hayashi Naomi, Nakamura Masanori, Hattori Norifumi, Sato Yusuke, Umeda Shinichi, Uehara Kei, Aiba Toshisada, Sonohara Fuminori, Hayashi Masamichi, Kanda Mitsuro, Kobayashi Daisuke, Tanaka Chie, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Murotani Kenta, Ando Masahiko, Ando Yuichi, Muro Kei, Kodera Yasuhiro
EUROPEAN JOURNAL OF CANCER Vol. 144 page： 61 - 71 2021.2
-
Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study
Tsubata Yukari, Shinomiya Shun, Inoue Koji, Ishikawa Nobuhisa, Saito Ryota, Nakashima Kazuhisa, Hotta Katsuyuki, Hamada Akinobu, Nagashima Fumio, Ando Yuichi, Morita Satoshi, Kobayashi Kunihiko, Isobe Takeshi
BMC GERIATRICS Vol. 21 ( 1 ) page： 74 2021.1
-
PhaseIIclinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors
Nishida Yoshihiro, Urakawa Hiroshi, Nakayama Robert, Kobayashi Eisuke, Ozaki Toshifumi, Ae Keisuke, Matsumoto Yoshihiro, Tsuchiya Hiroyuki, Goto Takahiro, Hiraga Hiroaki, Naka Norifumi, Takahashi Shunji, Ando Yuichi, Ando Masahiko, Kuwatsuka Yachiyo, Hamada Shunsuke, Ueda Takafumi, Kawai Akira
INTERNATIONAL JOURNAL OF CANCER Vol. 148 ( 1 ) page： 140 - 149 2021.1
-
Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial
Nishida Yoshihiro, Hamada Shunsuke, Urakawa Hiroshi, Ikuta Kunihiro, Sakai Tomohisa, Koike Hiroshi, Ito Kan, Emoto Ryo, Ando Yuichi, Matsui Shigeyuki
CANCER SCIENCE Vol. 111 ( 11 ) page： 4187 - 4194 2020.11
-
Chemotherapy for biliary tract cancer: real-world experience in a single institute
Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi
NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 4 ) page： 725 - 733 2020.11
-
Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review
Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi
NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 4 ) page： 631 - 644 2020.11
-
What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?
Ogura Atsushi, Uehara Kay, Aiba Toshisada, Hattori Norifumi, Nakayama Goro, Maeda Osamu, Ando Yuichi, Kodera Yasuhiro, Ebata Tomoki, Nagino Masato
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE Vol. 35 ( 11 ) page： 2073 - 2080 2020.11
-
Gap between pediatric and adult approvals of molecular targeted drugs
Nishiwaki Satoshi, Ando Yuichi
SCIENTIFIC REPORTS Vol. 10 ( 1 ) page： 17145 2020.10
-
Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer
Minami Hironobu, Ando Yuichi, Tamura Kenji, Tajima Takeshi, Isaacs Randi
ANTICANCER RESEARCH Vol. 40 ( 9 ) page： 5229 - 5235 2020.9
-
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter
Maeda Osamu, Shimokata Tomoya, Ando Yuichi
CLINICAL CANCER RESEARCH Vol. 26 ( 14 ) page： 3889 - 3889 2020.7
-
Experiences and hidden needs of older patients, their families and their physicians in palliative chemotherapy decision-making: a qualitative study
Tsuboi Rie, Sugishita Mihoko, Hirakawa Yoshihisa, Ando Yuichi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY Vol. 50 ( 7 ) page： 779 - 786 2020.7
-
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study
Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro
INTERNATIONAL JOURNAL OF CANCER Vol. 146 ( 12 ) page： 3504 - 3515 2020.6
-
Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies
Mizuno Kazuyuki, Ito Takanori, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Kawashima Hiroki, Inukai Yosuke, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Maeda Osamu, Kiyoi Hitoshi, Nagino Masato, Hibi Hideharu, Kodera Yasuhiro, Fujimoto Yasushi, Sone Michihiko, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Fujishiro Mitsuhiro
JOURNAL OF GASTROENTEROLOGY Vol. 55 ( 6 ) page： 653 - 661 2020.6
-
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
Nishida Yoshihiro, Urakawa Hiroshi, Nakayama Robert, Ozaki Toshifumi, Ae Keisuke, Matsumoto Yoshihiro, Ando Yuichi, Kuwatsuka Yachiyo, Ueda Takafumi, Kawai Akira
JOURNAL OF CLINICAL ONCOLOGY Vol. 38 ( 15 ) 2020.5
-
Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.
Miyai Yuki, Enomoto Atsushi, Ando Yuichi, Takahashi Masahide
JOURNAL OF CLINICAL ONCOLOGY Vol. 38 ( 15 ) 2020.5
-
Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi
BRITISH JOURNAL OF CANCER Vol. 122 ( 6 ) page： 771 - 777 2020.3
-
Detection of bacteria in blood circulation in patients receiving cancer chemotherapy
Ota Akiko, Morita Sachi, Matsuoka Ayumu, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Yagi Tetsuya, Asahara Takashi, Ando Yuichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY Vol. 25 ( 1 ) page： 210 - 215 2020.1
-
Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5 '-Deoxy-5-fluorocytidine, and Creatinine Clearance
Inaishi Takahiro, Fujita Ken-Ichi, Matsumoto Natsumi, Shimokata Tomoya, Maeda Osamu, Kikumori Toyone, Hattori Norifumi, Nakayama Goro, Ando Yuichi
IN VIVO Vol. 34 ( 6 ) page： 3539 - 3544 2020
-
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Okuji Takayuki, Ito Masaaki, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Hibi Hideharu, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi
JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 ( 2 ) 2020
-
Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan
Nishiwaki Satoshi, Ando Yuichi
JOURNAL OF GLOBAL ONCOLOGY Vol. 5 page： 1 - 3 2019.11
-
A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity
Matsuoka A., Mitsuma A., Maeda O., Tsunoda N., Kikumori T., Ando Y.
ANNALS OF ONCOLOGY Vol. 30 2019.10
-
Selection of chemotherapy based on geriatric assessment for elderly patients with pancreatic cancer
Maeda Osamu, Matsuoka Ayumu, Yanagawa Madoka, Muroyama Yukie, Kuzuya Masafumi, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 30 page： 131 - 131 2019.10
-
Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Wick W., Tabatabai G., Schuler M., Rorhberg K., Chawla S. P., Janku F., Schiff D., Heinemann V., Narita Y., Ando Y., Lenz H. J., Ikeda M., Genvresse I., Rentzsch C., Reschke S., Cyris C., Cai C., Jeffers M., Pena C., Baehr O.
ANNALS OF ONCOLOGY Vol. 30 page： 170 - + 2019.10
-
Recent progress of chemotherapy and biomarkers for gastroesophageal cancer
Maeda Osamu, Ando Yuichi
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY Vol. 11 ( 7 ) page： 518 - 526 2019.7
-
Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy
Maeda Osamu, Matsuoka Ayumu, Furukawa Kazuhiro, Miyahara Ryoji, Hirooka Yoshiki, Ando Yuichi
MOLECULAR AND CLINICAL ONCOLOGY Vol. 11 ( 1 ) page： 91 - 98 2019.7
-
Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.
Nishida Yoshihiro, Sakai Tomohisa, Shimizu Koki, Urakawa Hiroshi, Arai Eisuke, Ikuta Kunihiro, Ando Yuichi, Ishiguro Naoki
JOURNAL OF CLINICAL ONCOLOGY Vol. 37 ( 15 ) 2019.5
-
Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Wirth Lori J., Leboulleux Sophie, Kiyota Naomi, Tahara Makoto, Muro Kei, Ahn Myung-Ju, Ando Yuichi, Taylor Matthew H., Takahashi Shunji, Kim Sung-Bae, Misir Soamnauth, Dutcus Corina E., Xie Ran, Joshi Prashant Ramesh, Hughes Brett Gordon Maxwell, Aller Javier, Krzyzanowska Monika K., Capdevila Jaume
JOURNAL OF CLINICAL ONCOLOGY Vol. 37 ( 15 ) 2019.5
-
Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study
Takano Nao, Yamada Suguru, Hirakawa Akihiro, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Okada Tohru, Ohno Eizaburo, Yamaguchi Junpei, Ishikawa Takuya, Sonohara Fuminori, Suenaga Masaya, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Fuji Tsutomu, Kodera Yasuhiro
NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 81 ( 2 ) page： 233 - 239 2019.5
-
Phase I study of alpelisib (BYL719), an alpha-specific PI3K inhibitor, in Japanese patients with advanced solid tumors
Ando Yuichi, Iwasa Satoru, Takahashi Shunji, Saka Hideo, Kakizume Tomoyuki, Natsume Kazuto, Suenaga Naoko, Quadt Cornelia, Yamada Yasuhide
CANCER SCIENCE Vol. 110 ( 3 ) page： 1021 - 1031 2019.3
-
Modified Docetaxel plus Cisplatin plus Capecitabine (DCX) for Gastric Cancer
Maeda Osamu, Ando Yuichi, Matsuoka Ayumu, Furukawa Kazuhiro, Funasaka Kohei, Miyahara Ryoji, Hirooka Yoshiki, Goto Hidemi
DIGESTION Vol. 99 ( 1 ) page： 113 - 113 2019
-
Spiritual pain and care needs of elderly cancer patients facing palliative chemotherapy decision-making: Qualitative study.
Tsuboi Rie, Sugishita Mihoko, Hirakawa Hirohisa, Ando Yuichi
JOURNAL OF CLINICAL ONCOLOGY Vol. 36 ( 34 ) 2018.12
-
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma
Yonemori Kan, Kodaira Makoto, Satoh Taroh, Kudo Toshihiro, Takahashi Shunji, Nakano Kenji, Ando Yuichi, Shimokata Tomoya, Mori Joji, Inoue Koichi, Oakley Gerard J., Sakaguchi Sachi, Tamura Kenji
CANCER SCIENCE Vol. 109 ( 12 ) page： 3962 - 3970 2018.12
-
Reporting harms more transparently in trials of cancer drugs
Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi
BMJ-BRITISH MEDICAL JOURNAL Vol. 363 page： k4383 2018.11
-
Cabozantinib in Hepatocellular Carcinoma
Maeda Osamu, Ando Yuichi
NEW ENGLAND JOURNAL OF MEDICINE Vol. 379 ( 14 ) page： 1384 - 1384 2018.10
-
Cabozantinib in Hepatocellular Carcinoma.
Maeda O, Ando Y
The New England journal of medicine Vol. 379 ( 14 ) page： 1384 2018.10
-
A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity
Matsuoka A., Maeda O., Mitsuma A., Uehara K., Nakayama G., Nagino M., Kodera Y., Ando Y.
ANNALS OF ONCOLOGY Vol. 29 2018.10
-
Docetaxel, cisplatin and fluorouracil as neoadjuvant chemotherapy for esophageal cancer with prophylactic pegfilgrastim
Maeda Osamu, Koike Masahiko, Fukaya Masahide, Miyata Kazushi, Iwata Naoki, Nagino Masato, Kodera Yasuhiro, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 29 2018.10
-
Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas
Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 29 2018.10
-
Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies
Ando Yuichi, Doi Toshihiko, Mitsuma Ayako, Mizutani Takefumi, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Naito Yoichi, Matsubara Nobuaki, Ishihara Kae, Tajima Takeshi, Tokushige Kota, Cameron Scott, Minami Hironobu
ANNALS OF ONCOLOGY Vol. 29 2018.10
-
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
Nakayama Goro, Mitsuma Ayako, Sunagawa Yuki, Ishigure Kiyoshi, Yokoyama Hiroyuki, Matsui Takanori, Nakayama Hiroshi, Nakata Kazuhiko, Ishiyama Akiharu, Asada Takahiro, Umeda Shinichi, Ezaka Kazuhiro, Hattori Norifumi, Takami Hideki, Kobayashi Daisuke, Tanaka Chie, Kanda Mitsuro, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro
ONCOLOGIST Vol. 23 ( 8 ) page： 919 - 927 2018.8
-
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
Yamada Suguru, Fujii Tsutomu, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Suzuki Kojiro, Okada Tohru, Ono Eizaburo, Yamaguchi Junpei, Takano Nao, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Kodera Yasuhiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY Vol. 81 ( 5 ) page： 815 - 821 2018.5
-
Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Reviewed
Hiroaki Tsukuura, Masayuki Miyazaki, Tatsuya Morita, Mihoko Sugishita, Hiroshi Kato, Yuka Murasaki, Bishal Gyawali, Yoko Kubo, Masahiko Ando, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa and Yuichi Ando
Oncologist Vol. 23 ( 3 ) page： 367 - 374 2018.3
-
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi
JOURNAL OF THE ENDOCRINE SOCIETY Vol. 2 ( 3 ) page： 241 - 251 2018.3
-
Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).
Ezaka Kazuhiro, Nakayama Goro, Yokoyama Hiroyuki, Matsui Takanori, Umeda Shinichi, Sunagawa Yuki, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY Vol. 36 ( 4 ) 2018.2
-
Randomized phase II trial of CapOX plus bevacizumab versus CapIRI plus bevacizumab as first-line treatment in Japanese patients with metastatic colorectal cancer (CCOG-1201).
Sasahara Masahiro, Nakayama Goro, Ishigure Kiyoshi, Yokoyama Hiroyuki, Uehara Keisuke, Ishiyama Akiharu, Matsui Takanori, Nakayama Hiroshi, Kobayashi Daisuke, Umeda Shinichi, Sunagawa Yuki, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY Vol. 36 ( 4 ) 2018.2
-
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan. Reviewed
Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takehumi Mizutani, Tomoya Shimokata, Hiromichi Hayashi, Osamu Maeda and Yuichi Ando
Int J Clin Oncol Vol. 23 ( 1 ) page： 195 - 200 2018.2
-
Guidelines for treatment of renal injury during cancer chemotherapy 2016
Horie Shigeo, Oya Mototsugu, Nangaku Masaomi, Yasuda Yoshinari, Komatsu Yasuhiro, Yanagita Motoko, Kitagawa Yuko, Kuwano Hiroyuki, Nishiyama Hiroyuki, Ishioka Chikashi, Takaishi Hiromasa, Shimodaira Hideki, Mogi Akira, Ando Yuichi, Matsumoto Koji, Kadowaki Daisuke, Muto Satoru
CLINICAL AND EXPERIMENTAL NEPHROLOGY Vol. 22 ( 1 ) page： 210 - 244 2018.2
-
Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer. Reviewed
Naomi Hayashi, Ayumu Matsuoka, Hidemi Goto, Momokazu Gotoh, Hitoshi Kiyoi, Yasuhiro Kodera, Masato Nagino, Fumio Nagashima, Yuichi Ando.
J Geriatr Oncol Vol. 9 ( 1 ) page： 84 - 86 2018.1
-
Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 page： 69 - 69 2017.11
-
FDA Approval Summary: Sonidegib-Letter
Gyawali Bishal, Ando Yuichi
CLINICAL CANCER RESEARCH Vol. 23 ( 19 ) page： 5993 - 5993 2017.10
-
Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis
Maeda Osamu, Shimokata Tomoya, Mizutani Takefumi, Inoue Megumi, Matsuoka Ayumu, Ota Akiko, Mizuno Takashi, Ebata Tomoki, Nagino Masato, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 28 page： 50 - 50 2017.10
-
Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors
Gyawali B., Shimokata T., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 2017.9
-
A phase 1 study of BYL719, an a-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
Tomomatsu J., Iwasa S., Saka H., Takahashi S., Nakano K., Morita S., Inoue M., Nakahama H., Kogure Y., Kakizume T., Natsume K., Aoki T., Quadt C., Yamada Y., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 2017.9
-
Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.
Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F
Molecular and clinical oncology Vol. 7 ( 3 ) page： 510 2017.9
-
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
Nakayama Goro, Ishigure Kiyoshi, Yokoyama Hiroyuki, Uehara Keisuke, Kojima Hiroshi, Ishiyama Akiharu, Hayashi Naomi, Takano Nao, Hattori Norifumi, Kobayashi Daisuke, Tanaka Chie, Hayashi Masamichi, Kanda Mitsuro, Yamada Suguru, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro
BMC CANCER Vol. 17 ( 1 ) page： 243 2017.4
-
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials
Gyawali B., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 ( 4 ) page： 898 - 899 2017.4
-
Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer
Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi
BREAST CANCER Vol. 24 ( 2 ) page： 312 - 318 2017.3
-
[Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
Matsuoka A, Ando Y
Gan to kagaku ryoho. Cancer & chemotherapy Vol. 44 ( 3 ) page： 200 - 203 2017.3
-
Modified docetaxel, cisplatin and capecitabine for stage. gastric cancer in Japanese patients: A feasibility study
Maeda Osamu, Matsuoka Ayumu, Miyahara Ryoji, Funasaka Kohei, Hirooka Yoshiki, Fukaya Masahide, Nagino Masato, Kodera Yasuhiro, Goto Hidemi, Ando Yuichi
WORLD JOURNAL OF GASTROENTEROLOGY Vol. 23 ( 6 ) page： 1090 - 1097 2017.2
-
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials
Gyawali B., Shimokata T., Ando M., Honda K., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 ( 2 ) page： 246 - 253 2017.2
-
Unconvincing Benefit of Combination TherapyWith Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer
Ota Akiko, Gyawali Bishal, Matsuoka Ayumu, Ando Yuichi
JOURNAL OF CLINICAL ONCOLOGY Vol. 35 ( 6 ) page： 691 - + 2017.2
-
[Analysis of Nedaplatin Dose in Patients with Impaired Renal Function].
Araki R, Iwamizu H, Kataoka T, Kumakura Y, Miyazaki M, Nagai T, Ando Y, Yamada K
Gan to kagaku ryoho. Cancer & chemotherapy Vol. 44 ( 2 ) page： 143 - 147 2017.2
-
Carboplatin dosing for adult Japanese patients Invited Reviewed
Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, and Yoshinori Hasegawa.
Nagoya J Med Sci Vol. 76 ( 1 ) page： 1-9 2014.2
-
A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Reviewed
Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi.
Cancer Sci Vol. 105 ( 3 ) page： 347-53 2014.1
-
Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed
Cancer Sci Vol. 101 page： 2601-5 2010
-
UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Invited Reviewed
Yuichi Ando, et al.
Curr Opin Mol Ther Vol. 9 page： 258-262 2007
-
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Reviewed
Yuichi Ando, et al.
Cancer Res Vol. 60 page： 6921-6926 2000
Books 3
-
高齢者のがん薬物療法ガイドライン
統括委員長 安藤雄一
編集：日本臨床腫瘍学会・日本癌治療学会 2019.7
-
治療学 内科学総論 内科学書
安藤雄一（ Role： Contributor）
中山書店 2019
-
薬物動態・薬力学．新臨床腫瘍学 がん薬物療法専門医のために
安藤雄一（ Role： Contributor）
南江堂 2018
KAKENHI (Grants-in-Aid for Scientific Research) 16
-
抗がん薬による下痢・腸炎の病態解明と新治療法の開発
2017.4 - 2020.3
科学研究費補助金 基盤研究(C)
-
がん薬物療法におけるサルコペニアの臨床的意義
2014.4 - 2017.3
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
-
Study on proper use of oral anticoagulants combined with 5-fluorouracil
Grant number：22K06743 2022.4 - 2025.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Authorship：Coinvestigator(s)
-
Exploring biomarkers for immune checkpoint inhibitors in elderly patients with cancer
Grant number：22K07415 2022.4 - 2025.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Authorship：Coinvestigator(s)
-
Grant number：20H03528 2020.4 - 2023.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)
Authorship：Principal investigator
Grant amount：\17290000 （ Direct Cost: \13300000 、 Indirect Cost：\3990000 ）
-
Exploratory analysis of DNA methylation as a novel biomarker in gastrointestinal cancer chemotherapy
Grant number：20K08328 2020.4 - 2023.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Authorship：Coinvestigator(s)
-
がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出
Grant number：19K07083 2019.4 - 2023.3
科学研究費助成事業 基盤研究(C)
満間 綾子, 安藤 雄一, 下方 智也
Authorship：Coinvestigator(s)
新規抗がん薬の開発により、外来化学療法で取り扱う抗がん薬レジメンは増加する一方である。外来化学療法室の利用患者は年々増加し、多様なニーズに応えるがん薬物療法に習熟した医療者の関わりが重要となっている。がん薬物療法を専門とする医療者の育成、拡充にあたっては、専門的な教育・訓練とともに抗がん薬を扱う現場における医療者の安全、職場環境の整備も提唱されている。曝露防止のための機器開発が進む中で過去の報告は現状と乖離しており、医療者がコストと時間をかけてどこまで曝露対策を行うかの科学的実証は未確立である。本研究では、抗がん薬曝露の実態を経年的・経時的に調査し現状に即したエビデンスを創出する。
本研究では、がん薬物療法における抗がん薬曝露の実態を調査し、繰り返しモニタリングを行うことで、国内での閾値の設定や予防の根拠となるエビデンスを創出することを目的としている。当院外来化学療法室では、院内すべての点滴抗がん薬の外来投与を専任の医療者が担当している。年間10000件以上の実施にあたり、職業性曝露のモニタリングとして環境モニタリングと生物学的モニタリングの経年的実施を行う。
＜環境モニタリング＞
当院外来化学療法室での環境モニタリングを行うにあたり、モニタリングの手法、場所を絞り込んだ後に、抗がん薬曝露予防を目的とした機器導入、マニュアルの改訂・整備の現状を把握できている。閉鎖式薬物移送システム(closed system drug transfer device: CSTD) は、当院において抗がん薬のミキシングすべてには使用していない。揮発性抗がん薬にのみCSTDを使用している。これまでのモニタリング結果では既報に比べて汚染の度合いを示す測定値は低く、現状での手法により経時的にモニタリングを進めている。
＜生物学的モニタリング＞
外来化学療法室で実施する膀胱内注入後の抗がん薬曝露について、同意を得た患者および医療者の排尿より生物学的モニタリングを行う。ドキソルビシンの投与が予定されており、投与量、排尿回数など臨床薬理学的解析を加えて経時的変化を観察する予定であったが、昨年度同様、治療対象者が乏しい状況が続いている。
がん関連学会での情報収集を継続しているがCOVID-19によってオンライン対応が主体である。2021年7月、医療薬学フォーラム2021/第29回クリニカルファーマシーシンポジウムにて経過を報告したが、オンライン発表で聴講できる参加者が限られており双方向の議論の場が乏しい状況にある。
環境モニタリングは順調に推移している。新規薬剤の導入、併用レジメンの開発によりレジメン数は増えている。COVID-19による診療体制の変化はあるが、外来化学療法室を利用する患者は同程度であった。
昨年同様、生物学的モニタリングは対象患者が乏しい状況があった。
生物学的モニタリングの対象となる泌尿器疾患の患者が昨年同様減少している。がん薬物療法は新たな治療法による影響で方針変更はあり得るため、今後も対象患者があった場合は対応する。
現状では環境モニタリングを中心に遂行する。新規薬剤の導入、併用レジメンの開発によって、がん薬物療法の現場で使用する対象薬剤は既報とは大きく異なっており推進の価値があると研究代表者および研究分担者と討議した。今後も定期的に研究代表者および研究分担者間で意見交換を行い、研究の推進に努める。 -
Factors involved in the efficacy and safety of biopharmaceuticals
Grant number：19K07224 2019.4 - 2022.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Nakamura Katsunori
Authorship：Coinvestigator(s)
Proper use and selection of antibody drugs are considered to be of clinical significance.The main purpose of this study was to clarify what causes side effects of biological drug and what is the most suitable combination drug for reducing side effects of biological drug.Infusion reactions are controlled by dosing rate, additional doses of corticosteroids, and prophylactic administration of antihistamines and antipyretic analgesics.We analyzed the correlation between the frequency of infusion reactions of rituximab and FcRn genetic polymorphisms.Furthermore, the difference between the combination drugs was examined.
-
Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment
Grant number：17K08950 2017.4 - 2020.3
Ando Yuichi
Authorship：Principal investigator
Grant amount：\3510000 （ Direct Cost: \2700000 、 Indirect Cost：\810000 ）
By focusing on bacterial-translocation, phenomenon in which human intestinal bacteria migrate into circulating blood in human body via intestinal wall, using highly-sensitive detection assay for viable bacteria, I investigated whether bacteria in the blood would be associated with the occurrence of adverse effects of cancer chemotherapy. The results revealed that patients with cancer were always prone to bacterial-translocations regardless of the administration of anticancer drugs, suggesting that bacterial-translocation would be the cause of febrile neutropenia, infection, and diarrhea/enteritis, which are caused by cancer chemotherapy.
-
Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.
Grant number：16K08906 2016.4 - 2020.3
Mitsuma Ayako
Authorship：Coinvestigator(s)
Some newly developed cancer chemotherapy drugs cause hemorrhage or thrombosis as adverse event through inhibition of angiogenesis. Prolonged survival and aging of cancer patients lead to increase of patients using anticoagulats to prevent cardiovascular disease. In this study we evaluated risk of cancer associated thrombosis receiving outpatient treatment, including drug interactions. We compared our data with predictive model proposed in foreign studies. We found no difference in outcome of treatment with specific anticoagulants. Effects of cancer chemotherapy and condition of patients influenced clinical course of thrombosis.
-
Study of the infusion reaction by rituximab
Grant number：16K08374 2016.4 - 2019.3
Nakamura Katsunori
Authorship：Coinvestigator(s)
Infusion reaction is a side effect that occurs immediately after antibody drug administration, and its prediction is becoming very important. In this study, we identified infusion reaction risk factors by analyzing genetic polymorphisms in patients who developed adverse effects immediately after rituximab administration. [Significance] By identifying risk factors such as the effects of FcRn genetic polymorphism, it is expected that the optimal use of rituximab can be considered taking into consideration individual differences in their genetic polymorphism. [Importance] It is expected that this study may be generalized to antibody drugs and could be applied to "preclinical tests" performed prior to clinical trials where antibody drugs are first administered to humans.
-
Elucidation of sarcopenia mechanism in the cancer cachexia
Grant number：15K08906 2015.4 - 2019.3
Shimokata Tomoya
Authorship：Coinvestigator(s)
We evaluated the body composition, muscle mass and adipose tissue, in patients who received cancer pharmacotherapy to test a hypothesis that the adipose tissue plays an important role in the process to cancer cachexia. We analyzed the change of the body composition in patients who received monotherapy of the mTOR inhibitor more than six months retrospectively. The muscle mass significantly decreased, but there were no significant changes in the adipose tissue quantity. Also, we performed a cohort study to evaluate a body composition change and a metabolic rate as subjects in the patients prospectively. We accumulate 28 cases and final analysis is in progress.
-
Establishment of bone metastasis treatment by regulating hyaluronan network and osteoclast
Grant number：26462261 2014.4 - 2018.3
Urakawa Hiroshi
Authorship：Coinvestigator(s)
Bone metastases impair the quality of patients with malignancies. We focused on the co-effect of regulation of hyaluronan (HA) and bone modifying agents. We investigated the effects of 4-methylumbelliferone (MU) and/or bone modifying agents on HA expression in breast and lung cancer cell lines in addition to their tumorigenicity in vitro and in vivo. MU or zoledronic acid treatment individually suppressed proliferation, migration and invasion of breast and lung cancer cell lines, and combination treatment of MU and zoledronic acid showed synergistic effects. Combination therapy showed additive inhibitory effects on metastatic bone lesions in vivo, which paralleled the inhibition of HA accumulation by MU, and inhibition of osteoclastogenesis. These data suggest that inhibition of HA synthesis is a promising novel therapeutic candidate for bone metastasis in addition to bone modifying agents.
-
Clinical significance of sarcopenia in cancer chemotherapy
Grant number：26460626 2014.4 - 2018.3
Ando Yuichi
Authorship：Principal investigator
Grant amount：\3510000 （ Direct Cost: \2700000 、 Indirect Cost：\810000 ）
The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.
-
がん薬物療法における血管新生阻害薬の薬物効果予測因子としての眼底所見の探索的研究
2011.4 - 2013.3
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
-
がん薬物療法における薬剤誘発性ＱＴ延長の遺伝的要因を含めた患者要因
2008.4 - 2011.3
科学研究費補助金 基盤研究(C)
安藤 雄一
Authorship：Principal investigator